Slow-Release Isosorbide-5-Mononitrate for the Treatment of Angina Pectoris: Duration of Effects
Isosorbide dinitrate (ISDN) is widely used for the treatment of angina pectoris and has been shown to prolong exercise tolerance during acute and sustained therapy [1–8]. However, ISDN is poorly bioavailable after oral intake, and a marked inter-individual variation in plasma ISDN concentrations has been reported after oral doses during both acute and chronic therapy . After oral ingestion, ISDN is rapidly metabolized into 2- and 5-mononitrates, both of which are biologically active. Now commercially available in Europe, isosorbide-5-mononitrate (IS-5-MN) has a half-life of 4–6 h and is almost 100% bioavailable after oral ingestion . The latter makes this compound pharmacokinetically more desirable than its parent compound ISDN. Furthermore, a slow-release formulation of IS-5-MN providing high plasma levels for up to 24 h is now available which should theoretically offer advantages by exerting antianginal effects over a prolonged period of time.
KeywordsPlacebo Depression Europe Attenuation Cardiol
- 7.Rudolph W, Blasini R, Froer KL, Brügmann U, Mannes A, Hall D (1981) Effects of acute and chronic administration of isosorbide dinitrate, sustained-release form, in patients with angina pectoris. In: Lichtlen PR, Engel H-J, Schrey A, Swan HJC (eds) Nitrates III. Springer, Berlin Heidelberg New York, p 75CrossRefGoogle Scholar
- 9.Chasseaud LF, Taylor T (1981) Pharmacokinetics of isosorbide-5-mononitrate. In: Kaltenbach, Bussmann, Schrey (eds) Mononitrate workshop. Wolf, Munich, p 12Google Scholar
- 10.Thadani U, Hamilton S, Teague S, Brady D, White B (to be published) Circulatory and antianginal effects of isosorbide-5-mononitrate: slow-release formulation in angina pectoris.Google Scholar